Genetic hypercholesterolemia - Symptoms, Causes, Treatment & Prevention

```html

Overview

Genetic hypercholesterolemia (also called familial hypercholesterolemia, FH) is an inherited disorder that results in markedly elevated low‑density lipoprotein cholesterol (LDL‑C) from birth. The condition is caused by mutations in genes responsible for removing LDL particles from the bloodstream, most commonly the LDLR gene, but also APOB, PCSK9, and rarely LDLRAP1. Because the liver cannot efficiently clear LDL‑C, individuals develop cholesterol‑rich plaques in arteries early in life, dramatically increasing the risk of premature cardiovascular disease (CVD).

Who it affects: FH can be inherited in an autosomal‑dominant pattern (heterozygous FH) or, much more rarely, in an autosomal‑recessive pattern (homozygous FH). Heterozygous FH (HeFH) occurs in about 1 in 250–300 people worldwide, making it one of the most common monogenic disorders. Homozygous FH (HoFH) is far rarer, estimated at 1 in 300,000–500,000 births.

Prevalence: According to the World Health Organization and recent meta‑analyses, >20 million people globally carry heterozygous FH, yet >90 % remain undiagnosed and untreated (WHO, 2022). In the United States, the CDC’s Division of Cancer Prevention and Control estimates ~1.3 million Americans have HeFH, while National Lipid Association reports ≈ 15 % of premature myocardial infarctions are attributable to FH.

Symptoms

Because the disease is present from birth, most patients are asymptomatic in childhood. When symptoms appear, they are usually related to atherosclerotic disease or physical signs of cholesterol deposition.

• Tendon xanthomas – firm, yellowish nodules on the Achilles tendon, hands, elbows, or knees. Often the first clue in adults.
• Corneal arcus – a white‑gray ring around the outer edge of the cornea, common in FH patients over 40.
• Premature atherosclerotic cardiovascular disease – chest pain (angina), shortness of breath, or sudden cardiac death before age 55 in men and 65 in women.
• Early‑onset peripheral artery disease – claudication, ulcerations, or gangrene in the legs.
• Stroke or transient ischemic attack (TIA) – especially in younger individuals (under 60).
• Family history – early heart attacks, hypercholesterolemia, or xanthomas in first‑degree relatives.

In homozygous FH, symptoms can begin in infancy or early childhood, including:

• Severe, untreated LDL‑C > 500 mg/dL (12.9 mmol/L).
• Extensive xanthomas on the skin, tendons, and even the eyelids (xanthelasma).
• Rapid development of aortic valve disease or aortic stenosis.
• Early heart failure or myocardial infarction before age 20.

Causes and Risk Factors

Genetic mutations

• LDLR (low‑density lipoprotein receptor) gene – accounts for ~80 % of FH cases.
• APOB (apolipoprotein B) gene – defective ApoB impairs LDL binding to its receptor.
• PCSK9 gain‑of‑function mutations – increase LDL‑R degradation, raising LDL‑C.
• LDLRAP1 – cause autosomal‑recessive FH when both copies are defective.

Inheritance patterns

• Autosomal‑dominant (heterozygous FH) – each child has a 50 % chance of inheriting the mutation.
• Autosomal‑recessive (homozygous FH) – requires two defective alleles; often seen in consanguineous families.

Additional risk modifiers

• Sex – men tend to develop cardiovascular events earlier.
• Lifestyle factors – smoking, sedentary behavior, and a diet high in saturated fat accelerate plaque formation.
• Co‑existing conditions – hypertension, diabetes, or chronic kidney disease increase absolute risk.

Diagnosis

The goal is to identify the condition early, confirm the genetic basis, and assess cardiovascular risk.

Clinical criteria

• Simon Broome Register (UK) – uses LDL‑C levels, presence of tendon xanthomas, and family history.
• Dutch Lipid Clinic Network (DLCN) score – assigns points for LDL‑C, clinical signs, family history, and genetic testing; ≥6 points = “definite FH”.

Laboratory tests

• Lipid panel – fasting LDL‑C ≥ 190 mg/dL (4.9 mmol/L) in adults suggests FH; in children, LDL‑C ≥ 160 mg/dL (4.1 mmol/L) is concerning.
• Apolipoprotein B and Lp(a) – may be elevated and provide additional risk information.

Genetic testing

DNA sequencing of the LDLR, APOB, and PCSK9 genes can confirm FH in > 80 % of clinically suspected cases. Testing is recommended for:

• Individuals with a DLCN score ≥6.
• First‑degree relatives of a confirmed case (cascade screening).

Guidelines from the American College of Cardiology (ACC) and the European Society of Cardiology (ESC) endorse genetic testing when available because it guides cascade screening and improves adherence to treatment (ACC/AHA, 2022).

Cardiovascular assessment

• Baseline electrocardiogram (ECG) and echocardiography to detect silent ischemia or valve disease.
• Coronary artery calcium (CAC) scoring or CT angiography for quantifying atherosclerotic burden, especially in asymptomatic adults.

Treatment Options

Treatment aims to lower LDL‑C as early and as aggressively as possible to prevent atherosclerosis.

First‑line pharmacotherapy

• Statins (e.g., atorvastatin, rosuvastatin) – inhibit HMG‑CoA reductase, typically reduce LDL‑C by 30‑50 % at moderate doses; high‑intensity statins achieve ≥ 50 % reduction.
• Ezetimibe – blocks intestinal cholesterol absorption; adds ~15‑20 % LDL‑C lowering when combined with statins.

Second‑line and adjunctive agents

• PCSK9 inhibitors (alirocumab, evolocumab) – monoclonal antibodies that prevent LDL‑R degradation; lower LDL‑C by 50‑60 % and have proven cardiovascular outcome benefit (FOURIER & ODYSSEY trials).
• Bile‑acid sequestrants (cholestyramine, colesevelam) – modest LDL‑C reduction (10‑20 %).
• Inclisiran – small interfering RNA that reduces PCSK9 synthesis; administered twice yearly after the initial loading dose.
• Lomitapide and Mipomersen – approved for HoFH; lower LDL‑C by 30‑50 % but have hepatic toxicity monitoring requirements.

Lipid‑apheresis

For patients with HoFH or severe HeFH who cannot reach target LDL‑C despite maximal medical therapy, weekly or bi‑weekly plasma filtration removes LDL particles directly. It can lower LDL‑C by 60‑70 % and has been shown to reduce cardiovascular events in HoFH (EuroLipidoid Registry, 2021).

Lifestyle modifications (essential for every patient)

1. Diet – adopt a Mediterranean‑style diet rich in fruits, vegetables, whole grains, nuts, oily fish, and olive oil; limit saturated fat (<7 % of total calories) and trans‑fat.
2. Physical activity – ≥ 150 minutes of moderate‑intensity aerobic exercise per week (e.g., brisk walking, cycling).
3. Weight management – maintain BMI 18.5–24.9 kg/m².
4. Smoking cessation – nicotine dramatically increases plaque instability.
5. Alcohol moderation – ≤ 2 drinks/day for men, ≤ 1 drink/day for women.

Target LDL‑C levels

• Adults with HeFH – aim for LDL‑C < 70 mg/dL (1.8 mmol/L) or ≥ 50 % reduction from baseline.
• Adults with HoFH – aim for LDL‑C < 100 mg/dL (2.6 mmol/L) or as low as feasible; many require < 30 mg/dL using combination therapy.
• Children (≥ 10 years) – target LDL‑C < 130 mg/dL (3.4 mmol/L); earlier statin initiation is safe and improves long‑term outcomes (JACC, 2020).

Living with Genetic Hypercholesterolemia

Successful management is a lifelong partnership between the patient, family, and healthcare team.

Practical daily tips

• Medication adherence – set daily alarms, use pill organizers, and keep a medication list.
• Regular lipid monitoring – check fasting LDL‑C every 3–6 months after therapy changes; annually once stable.
• Family cascade screening – encourage first‑degree relatives to be tested; early detection saves lives.
• Vaccinations – keep flu and COVID‑19 vaccinations up to date; infections can destabilize plaques.
• Stress management – chronic stress raises cortisol and can impair lipid metabolism; practice mindfulness, yoga, or counseling.
• Travel preparation – carry medication copies, a list of generic names, and a brief medical summary for emergency care abroad.

Psychosocial considerations

Living with a hereditary condition can cause anxiety or guilt. Support groups (e.g., FH Foundation), counseling, and patient education improve quality of life and medication compliance (Mayo Clinic, 2021).

Prevention

While the genetic defect cannot be removed, the impact on cardiovascular risk can be dramatically reduced.

• Early detection – universal cholesterol screening at ages 9–11 and again at 17–21 (AAP recommendation) catches many cases before damage accrues.
• Prenatal or pre‑implantation genetic testing – available for families with known pathogenic mutations who wish to avoid transmission.
• Aggressive risk factor control – managing hypertension, diabetes, and smoking multiplies the benefit of LDL‑C lowering.
• Public awareness – community screening programs and education reduce the >90 % under‑diagnosis rate.

Complications

If untreated or inadequately treated, FH leads to accelerated atherosclerosis and associated sequelae.

• Premature coronary artery disease (CAD) – leading cause of death; up to 50 % of HeFH patients experience a myocardial infarction before age 60.
• Ischemic stroke – particularly in younger adults.
• Peripheral arterial disease (PAD) – claudication, limb ischemia, and non‑healing ulcers.
• Aortic valve disease – calcific aortic stenosis is more common in FH patients over 40.
• Pancreatitis – very high triglyceride levels (often with secondary metabolic disorders) can trigger acute pancreatitis.
• Liver dysfunction – from certain lipid‑lowering drugs (e.g., lomitapide) or from fatty liver disease secondary to metabolic syndrome.

When to Seek Emergency Care

References

1. Mayo Clinic. Familial hypercholesterolemia. Mayo Clinic Proceedings. 2021.
2. World Health Organization. Global health estimates on familial hypercholesterolemia. 2022.
3. American College of Cardiology/American Heart Association. 2022 Guideline on the Management of Blood Cholesterol. Circulation. 2022.
4. European Society of Cardiology. ESC Guidelines for the Management of Dyslipidaemias. 2022.
5. JACC. Long‑term safety of statins initiated in childhood for FH. 2020.
6. FOURIER and ODYSSEY Outcomes Trials. PCSK9 inhibition and cardiovascular outcomes. 2019‑2020.
7. Cleveland Clinic. Familial hypercholesterolemia – patient resources.
8. National Lipid Association. FH and Cardiovascular Risk. 2021.
9. EuroLipidoid Registry. Clinical outcomes with LDL‑apheresis in HoFH. 2021.

```